Knott David M Jr Lowers Holdings in Autolus Therapeutics PLC Sponsored ADR $AUTL

Knott David M Jr lowered its stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 35.7% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 270,000 shares of the company’s stock after selling 150,000 shares during the quarter. Knott David M Jr’s holdings in Autolus Therapeutics were worth $616,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Wellington Management Group LLP grew its position in shares of Autolus Therapeutics by 6.9% during the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock valued at $41,992,000 after purchasing an additional 1,746,020 shares in the last quarter. Armistice Capital LLC boosted its stake in Autolus Therapeutics by 19.6% during the first quarter. Armistice Capital LLC now owns 11,000,000 shares of the company’s stock valued at $17,050,000 after buying an additional 1,800,000 shares during the last quarter. Atle Fund Management AB boosted its stake in Autolus Therapeutics by 130.5% during the second quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock valued at $2,520,000 after buying an additional 625,817 shares during the last quarter. Cetera Investment Advisers grew its holdings in Autolus Therapeutics by 17.6% during the 2nd quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock valued at $1,407,000 after buying an additional 92,300 shares in the last quarter. Finally, Aubrey Capital Management Ltd increased its stake in Autolus Therapeutics by 276.8% in the 2nd quarter. Aubrey Capital Management Ltd now owns 452,200 shares of the company’s stock worth $1,045,000 after acquiring an additional 332,202 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Up 7.0%

AUTL stock opened at $1.37 on Monday. Autolus Therapeutics PLC Sponsored ADR has a twelve month low of $1.11 and a twelve month high of $3.45. The stock has a market capitalization of $364.61 million, a price-to-earnings ratio of -1.65 and a beta of 1.84. The firm’s fifty day simple moving average is $1.50 and its two-hundred day simple moving average is $1.81.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%.The firm had revenue of $21.14 million for the quarter, compared to analysts’ expectations of $21.08 million. As a group, equities research analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday. Wells Fargo & Company decreased their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Finally, Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, November 3rd. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.15.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.